- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Leukemias | Clinical
NCCN Update to ALL Guideline Places Greater Emphasis on Philadelphia Chromosome Status
November 16, 2021
The National Comprehensive Cancer Network has updated its guidelines on ALL in adolescents and young adults.
Improved Sensitivity, Monitoring Needed for MRD in Adult and Pediatric ALL
October 18, 2021
Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.
Zanubrutinib for B-Cell Lymphomas
October 15, 2021
Drs Shadman and Cohen review clinical trials of zanubrutinib in B-cell lymphomas.
Disease Progression and Resistance to BTK Inhibitors
October 15, 2021
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.
FDA Approves Brexucabtagene Autoleucel for Adults With Relapsed/Refractory ALL
October 01, 2021
The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
SY-2101 Treatment Initiated in Patients With Newly-Diagnosed Acute Promyelocytic Leukemia
October 01, 2021
Treatment with the investigational agent SY-2101 has begun in a phase 3 clinical trial of patients with newly-diagnosed acute promyelocytic leukemia.
The Future of Myelodysplastic Syndrome
September 22, 2021
An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.
Emerging First-Line Treatments for High-Risk Myelodysplastic Syndrome
September 22, 2021
Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.
Treating Patients with High-Risk Myelodysplastic Syndrome
September 22, 2021
An expert details the treatment options for high-risk myelodysplastic syndrome.
Treatment Options for Low-Risk Myelodysplastic Syndrome
September 22, 2021
Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.